Assessing the risk of adverse pregnancy outcomes and birth defects reporting in women exposed to ganciclovir or valganciclovir during pregnancy: a pharmacovigilance study.

Adrien ContejeanMarianne Leruez-VilleJean-Marc TreluyerVassilis TsatsarisYves VilleCaroline Charlier Laurent Chouchana

Published in: The Journal of antimicrobial chemotherapy (2023)

These preliminary results require confirmation but suggest the possibility for trial evaluation of val(ganciclovir) in severe maternal or fetal CMV infections.

Keyphrases

pregnancy outcomes
pregnant women
adverse drug
clinical trial
study protocol
drug induced
early onset
randomized controlled trial
type diabetes
body mass index
emergency department
gestational age
birth weight
weight loss
preterm birth